Skip to main content

Alector AD

All trials

Alzheimer

Alector AD

Leeftijd icoon
50 - 85 years (M / F)
Diagnose icoon
Dementia due to Alzheimer's disease
Duratie onderzoek
112 weeks
Locatie icoon
Amsterdam, Den Bosch and Zwolle

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently.

A phase II, multicentre, double-blind, randomized, placebo-controlled study of the safety and efficacy of the drug AL002 in participants with mild to moderate Alzheimer’s disease.

This study will determine whether the study drug, called AL002, is effective and safe compared to a placebo (drug without an active ingredient) for the treatment of people with early-stage Alzheimer’s disease. With this study, the researchers want to find out more about the safety and working mechanisms of the drug. The study drug is administered by IV.

You and your research partner will come to the research center a maximum of about 32 times, during about 28 months. Each study visit lasts approximately three to six hours, depending on the procedures performed during that visit. You must fast (no food or drink, except water) prior to some blood tests.

The research is carried out in the Brain Research Center Amsterdam, Den Bosch, and Zwolle.

This study is commissioned by Alector.

This text has been directly translated from the Dutch trial description as approved by the Ethical Committee.

Screening - Selection

During 2 visits during the 4-week screening period, it is determined whether you meet the study criteria and whether your general health allows participation in the study. If so, you can participate. The selection takes place at one of our locations in Amsterdam, Den Bosch, and Zwolle, and includes blood tests, physical examinations, memory tests, ECG questionnaires, Eye examination, MRI, PET scan, and a spinal tap.

Treatment

In this study, the study drug is compared to a placebo. The chance that you will receive the study drug compared to placebo is 3 to 1. An IV treatment will take place every 4 weeks. In addition, agreements will be made with you when you should come to our center for check-ups (inquiries about side effects and medication use) and there will be physical and neurological examinations and neuropsychological examinations, in addition to ophthalmic examinations, spinal tap, EKGs, MRI scans. and PET scan. The duration of treatment is 48 or 96 weeks.

Follow-up

After completing the treatment phase, participants will be followed for up to 8 weeks and will return to the center for a follow-up. During these visits, questionnaires and tests will be taken for your memory, and among other things, blood tests, physical examinations, a PET scan, and/or a spinal tap will be performed.

Who can participate?

  • You have a diagnosis of dementia due to Alzheimer’s disease.
  • You are between 50 and 85 years old.
  • You weigh between 45 and 120 kg.
  • You have someone close to you/a caregiver who can accompany you during the visits to the research center and answer questions about your health and functioning.

Take action against Alzheimer’s. Sign up to participate.

Latest Dementia trials

Filter

All trialsAlzheimer

REMAD 02

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer's disease

duration9 weeks

locationAmsterdam

All trialsAlzheimer

APOLLOE4

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.

audience50 - 80 years

level Early-stage Alzheimer’s disease and ApoE4/4 genotype

duration93 weeks

locationAmsterdam, Den Bosch, and Zwolle

All trialsAlzheimer

Together

The goal of this study is to evaluate the safety and potential effectiveness of the…

The goal of this study is to evaluate the safety and potential effectiveness of the investigational drug (bepranemab) for participants with MCI or mild Alzheimer’s Disease. The study compares the effect of the active study drug bepranemab with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). Using a placebo will help us identify improvements or side effects which are caused by the active study medication. The study drug is administered through an intravenous (IV) injection.

audience50 - 80 years

levelMild cognitive impairment (MCI) or mild Alzheimer’s disease

duration152 weeks

locationAmsterdam, Den Bosch, and Zwolle